ELTROMBOPAG IN CHRONIC LIVER DISEASE PATIENTS WITH THROMBOCYTOPENIA UNDERGOING AN ELECTIVE INVASIVE PROCEDURE: RESULTS FROM ELEVATE, A RANDOMISED CLINICAL TRIAL

초록

Background and Aims: Eltrombopag, an orally active thrombo poietin-receptor agonist, has been shown to increase platelet count in patients with liver disease. This study evaluated the effects of eltrombopag in reducing the need for platelet transfusion in thrombocytopenic subjects with chronic liver disease (CLD) undergoing an elective invasive procedure.